Keros Therapeutics, Inc.
KROS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $244M | $3.55M | +6,775% |
| Operating income | $67.6M | −$211M | |
| Net income | $87.0M | −$187M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $40.0M | $14.1M | +184% |
| Operating income | $12.8M | −$15.4M | |
| Net income | $14.2M | −$7.30M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Keros Therapeutics's revenue in FY2025?
- $244M in FY2025 (Fiscal year ended Dec 31, 2025), +6,775% vs $3.55M a year earlier, per its 10-K filed Mar 2026.
- Was Keros Therapeutics profitable in FY2025?
- Yes: net income was $87.0M and operating income $67.6M in FY2025.
- What was Keros Therapeutics's revenue in Q3 2026?
- $40.0M (+184% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.